Breaking News & Top Stories
Interim findings from the DESTINY Breast09 trial reveal promising efficacy for trastuzumab deruxtecan, potentially reshaping first-line treatment for patients with HER2 positive metastatic breast cancer. The study compares this innovative…
Bayer AG has received approval from the US Food and Drug Administration (FDA) for its new medication, Hyrnuo, targeted at treating a prevalent form of lung cancer. This approval is…
Research published in the November 2025 issue of the Journal of Nuclear Medicine reveals a promising new radioimmunotherapy approach for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer.…
The landscape of treatment for HER2-mutated non-small cell lung cancer (NSCLC) is evolving rapidly. Recent therapeutic developments, including the swift approval of new therapies, underscore the importance of integrating patient…